EGFR and Alzheimer disease: The 3-year survival rates of patients with advanced-stage EGFR variation–positive AD who had received first line EGFR-TKI were 48.0% (95% CI, 45.0%-51.1%) in period I and 57.0% (95% CI, 54.0%-60.1%) in period II (P < .0001).